CSL +2.61% — Healthcare Leads as the Comeback Debate Opens
CSL surged +2.61% to $388.40, making it the session's strongest performer by a wide margin and the sole engine of Healthcare +2.61%. CSL's recent narrative has been one of reversal from a multi-year premium to discount: Motley Fool asks whether the 'once untouchable, now unloved' CSL is staging a genuine comeback or whether today's move is a dead-cat bounce on cheap valuation. For superannuation funds — the structural bid for ASX 200 quality — CSL is a core holding, and a sustained recovery matters for the broader index multiple. The plasma margin recovery thesis (post-COVID donation volumes returning to normal) is the fundamental catalyst to watch; until that prints in H2 FY26 results, today's move is an event-driven bid rather than earnings confirmation.
Read at Motley Fool Australia ↗